ClinicalTrials.Veeva

Menu

Continuous Glucose Sensor Profiles in Non-Diabetic Subjects

Jaeb Center for Health Research logo

Jaeb Center for Health Research

Status and phase

Completed
Phase 4

Conditions

Healthy Subjects Without Type 1 Diabetes

Treatments

Device: Continuous glucose monitor

Study type

Interventional

Funder types

Other
NETWORK

Identifiers

NCT00717977
2008-2403

Details and patient eligibility

About

The Juvenile Diabetes Research Foundation (JDRF) Glucose Sensor Study group is carrying out a large, randomized clinical trial to assess the efficacy, safety and cost-effectiveness of use of real-time continuous glucose monitors (RT-CGM) as an adjunct to standard meter plasma glucose testing. Although the primary outcome in the >= 7.0% cohort is differences in HbA1c levels, important secondary outcomes are differences in the percent of glucose sensor values either above or below the target glucose range of 70-180 mg/dl and differences in glucose variability. Prevention of biochemical hypoglycemia is a particularly important outcome in the low HbA1c cohort. Since CGM systems measure interstitial rather than plasma glucose and CGM values differ from simultaneous plasma glucose values by up to 18%, it would be extremely useful for comparative purposes to establish a reference range of sensor values in healthy, non-diabetic control subjects for this study and other future investigations. The objective of this protocol is to establish such reference sensor glucose ranges in each of the 3 devices being utilized in the JDRF study.

Full description

  1. After initial eligibility is determined, informed consent and assent are obtained from the parent/guardian and subject.

  2. Subjects will have the following tests performed:

    • Hemoglobin A1c (using the DCA2000 or equivalent device)

    • Oral glucose tolerance test to obtain fasting and 2 hour plasma glucose levels

    • Anti-GAD, anti-IA2 and anti-insulin antibodies

      • Subjects with an HbA1c >6.0% and/or fasting glucose levels >100 and/or 2 hour glucose levels >140 will be discontinued from the study.
  3. Subjects with normal A1c and glucose levels will be provided with an RT-CGM and home glucose meter (HGM)

  4. An RT-CGM sensor will be inserted and initiated by study personnel.

  5. Subjects who would like to wear 2 sensors will be given 2 of the same type of RT-CGM.

  6. Subjects will be instructed to wear the sensor for 3-7 days (depending on the type of device) and measure the blood glucose on the HGM as needed to calibrate the sensor.

  7. Subjects will return to the clinical center after the 3-7 days of sensor wear to return the RT-CGM and HGM.

    • If the subject has less than 48 hours of sensor data he or she will be asked to wear another sensor and return 3-7 days later.

Enrollment

74 patients

Sex

All

Ages

8+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age > 8 years
  • Body mass index (BMI) between the 10th to 90th percentile for age and sex (based on CDC, 2000 nomogram) and < 28 kg body weight/meter in adult subjects
  • No significant chronic illness or taking any acute or chronic medications that might affect glucose metabolism.

Exclusion criteria

  • History of diabetes or positive islet cell antibody testing

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems